Liquid AI Releases World’s Fastest and Best-Performing Open-Source Small Foundation Models
10.7.2025 15:00:00 CEST | Business Wire | Press Release
Liquid AI announced today the launch of its next-generation Liquid Foundation Models (LFM2), which set new records in speed, energy efficiency, and quality in the edge model class. This release builds on Liquid AI’s first-principles approach to model design. Unlike traditional transformer-based models, LFM2 is composed of structured, adaptive operators that allow for more efficient training, faster inference and better generalization – especially in long-context or resource-constrained scenarios.
Liquid AI open-sourced its LFM2, introducing the novel architecture in full transparency to the world. LFM2’s weights can now be downloaded from Hugging Face and are also available through the Liquid Playground for testing. Liquid AI also announced that the models will be integrated into its Edge AI platform and an iOS-native consumer app for testing in the following days.
“At Liquid, we build best-in-class foundation models with quality, latency, and memory efficiency in mind,” said Ramin Hasani, co-founder and CEO of Liquid AI. “LFM2 series of models is designed, developed, and optimized for on-device deployment on any processor, truly unlocking the applications of generative and agentic AI on the edge. LFM2 is the first in the series of powerful models we will be releasing in the coming months.”
The release of LFM2 marks a milestone in global AI competition and is the first time a U.S. company has publicly demonstrated clear efficiency and quality gains over China’s leading open-source small language models, including those developed by Alibaba and ByteDance.
In head-to-head evaluations, LFM2 models outperform state-of-the-art competitors across speed, latency and instruction-following benchmarks. Key highlights:
- LFM2 exhibits 200 percent higher throughput and lower latency compared to Qwen3, Gemma 3n Matformer and every other transformer- and non-transformer-based autoregressive models available to date, on CPU.
- The model not only is the fastest, but also on average performs significantly better than models in each size class on instruction-following and function calling (the main attributes of LLMs in building reliable AI agents). This places LFM2 as the ideal choice of models for local and edge use-cases.
- LFMs built based on this new architecture and the new training infrastructure show 300 percent improvement in training efficiency over the previous versions of LFMs, making them the most cost-efficient way to build capable general-purpose AI systems.
Shifting large generative models from distant clouds to lean, on‑device LLMs unlocks millisecond latency, offline resilience, and data‑sovereign privacy. These are capabilities essential for phones, laptops, cars, robots, wearables, satellites, and other endpoints that must reason in real time. Aggregating high‑growth verticals such as edge AI stack in consumer electronics, robotics, smart appliances, finance, e-commerce, and education, before counting defense, space, and cybersecurity allocations, pushes the TAM for compact, private foundation models toward the $1 trillion mark by 2035.
Liquid AI is engaged with a large number of Fortune 500 companies in these sectors. They offer ultra‑efficient small multimodal foundation models with a secure enterprise-grade deployment stack that turns every device into an AI device, locally. This gives Liquid AI the opportunity to obtain an outsized share on the market as enterprises pivot from cloud LLMs to cost-efficient, fast, private and on‑prem intelligence.
About Liquid AI:
Liquid AI is at the forefront of artificial intelligence innovation, developing foundation models that set new standards for performance and efficiency. With the mission to build efficient, general-purpose AI systems at every scale, Liquid AI continues to push the boundaries of how much intelligence can be packed into phones, laptops, cars, satellites, and other devices. Learn more at www.liquid.ai.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250710527694/en/
Contacts
Media:
Stephen Peters
stephen.peters@liquid.ai
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom